Marinus Pharmaceuticals Provides SBECD-enabled Ganaxolone Clinical Data
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced it
Tag: Marinus
Marinus Awarded BARDA Contract to Develop SBECD-enabled Ganaxolone for Treatment of Refractory Status Epilepticus
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced it has
Marinus Data from SBECD-enabled Ganaxolone Phase 2 Trial in Refractory Status Epilepticus
Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric
Positive Results With SBECD-enabled Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders,